97 related articles for article (PubMed ID: 33303690)
1. AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin Signaling.
Gao SP; Kiliti AJ; Zhang K; Vasani N; Mao N; Jordan E; Wise HC; Shrestha Bhattarai T; Hu W; Dorso M; Rodrigues JA; Kim K; Hanrahan AJ; Razavi P; Carver B; Chandarlapaty S; Reis-Filho JS; Taylor BS; Solit DB
Mol Cancer Res; 2021 Apr; 19(4):573-584. PubMed ID: 33303690
[TBL] [Abstract][Full Text] [Related]
2. PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.
Beaver JA; Gustin JP; Yi KH; Rajpurohit A; Thomas M; Gilbert SF; Rosen DM; Ho Park B; Lauring J
Clin Cancer Res; 2013 Oct; 19(19):5413-22. PubMed ID: 23888070
[TBL] [Abstract][Full Text] [Related]
3. Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations.
Lauring J; Cosgrove DP; Fontana S; Gustin JP; Konishi H; Abukhdeir AM; Garay JP; Mohseni M; Wang GM; Higgins MJ; Gorkin D; Reis M; Vogelstein B; Polyak K; Cowherd M; Buckhaults PJ; Park BH
Oncogene; 2010 Apr; 29(16):2337-45. PubMed ID: 20101210
[TBL] [Abstract][Full Text] [Related]
4. Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with
Smyth LM; Tamura K; Oliveira M; Ciruelos EM; Mayer IA; Sablin MP; Biganzoli L; Ambrose HJ; Ashton J; Barnicle A; Cashell DD; Corcoran C; de Bruin EC; Foxley A; Hauser J; Lindemann JPO; Maudsley R; McEwen R; Moschetta M; Pass M; Rowlands V; Schiavon G; Banerji U; Scaltriti M; Taylor BS; Chandarlapaty S; Baselga J; Hyman DM
Clin Cancer Res; 2020 Aug; 26(15):3947-3957. PubMed ID: 32312891
[TBL] [Abstract][Full Text] [Related]
5. Human NUMB6 Induces Epithelial-Mesenchymal Transition and Enhances Breast Cancer Cells Migration and Invasion.
Karaczyn AA; Adams TL; Cheng RY; Matluk NN; Verdi JM
J Cell Biochem; 2017 Feb; 118(2):237-251. PubMed ID: 27302072
[TBL] [Abstract][Full Text] [Related]
6. A gain of function mutation in AKT1 increases hexokinase 2 and diminishes oxidative stress in meningioma.
Singh S; Lathoria K; Umdor SB; Singh J; Suri V; Sen E
Cytokine; 2024 Apr; 176():156535. PubMed ID: 38325141
[TBL] [Abstract][Full Text] [Related]
7. Recurrent AKT mutations in human cancers: functional consequences and effects on drug sensitivity.
Yi KH; Lauring J
Oncotarget; 2016 Jan; 7(4):4241-51. PubMed ID: 26701849
[TBL] [Abstract][Full Text] [Related]
8. A protein-targeting strategy used to develop a selective inhibitor of the E17K point mutation in the PH domain of Akt1.
Deyle KM; Farrow B; Qiao Hee Y; Work J; Wong M; Lai B; Umeda A; Millward SW; Nag A; Das S; Heath JR
Nat Chem; 2015 May; 7(5):455-62. PubMed ID: 25901825
[TBL] [Abstract][Full Text] [Related]
9. AKT1/BRCA1 in the control of homologous recombination and genetic stability: the missing link between hereditary and sporadic breast cancers.
Guirouilh-Barbat J; Wilhelm T; Lopez BS
Oncotarget; 2010 Dec; 1(8):691-699. PubMed ID: 21321378
[TBL] [Abstract][Full Text] [Related]
10. AKT2 Loss Impairs BRAF-Mutant Melanoma Metastasis.
McRee SK; Bayer AL; Pietruska J; Tsichlis PN; Hinds PW
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894325
[TBL] [Abstract][Full Text] [Related]
11. Membrane Recruitment as a Cancer Mechanism: A Case Study of Akt PH Domain.
Falke JJ
Cellscience; 2007; 4(2):25-30. PubMed ID: 19079757
[TBL] [Abstract][Full Text] [Related]
12. Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.
Fujimoto Y; Morita TY; Ohashi A; Haeno H; Hakozaki Y; Fujii M; Kashima Y; Kobayashi SS; Mukohara T
Sci Rep; 2020 Dec; 10(1):21762. PubMed ID: 33303839
[TBL] [Abstract][Full Text] [Related]
13. LncRNA NEAT1 promotes gastric cancer progression via miR-1294/AKT1 axis.
Wu D; Li H; Wang J; Li H; Xiao Q; Zhao X; Huo Z
Open Med (Wars); 2020; 15(1):1028-1038. PubMed ID: 33336058
[TBL] [Abstract][Full Text] [Related]
14. Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools.
Gerratana L; Davis AA; Polano M; Zhang Q; Shah AN; Lin C; Basile D; Toffoli G; Wehbe F; Puglisi F; Behdad A; Platanias LC; Gradishar WJ; Cristofanilli M
Eur J Cancer; 2021 Jan; 143():147-157. PubMed ID: 33307492
[TBL] [Abstract][Full Text] [Related]
15. TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer.
da Silva EM; Selenica P; Vahdatinia M; Pareja F; Da Cruz Paula A; Ferrando L; Gazzo AM; Dopeso H; Ross DS; Bakhteri A; Riaz N; Chandarlapaty S; Razavi P; Norton L; Wen HY; Brogi E; Weigelt B; Zhang H; Reis-Filho JS
NPJ Breast Cancer; 2021 Apr; 7(1):43. PubMed ID: 33863915
[TBL] [Abstract][Full Text] [Related]
16. Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women.
Filippova OT; Selenica P; Pareja F; Vahdatinia M; Zhu Y; Pei X; Riaz N; Long Roche K; Chi DS; Abu-Rustum NR; Ellenson LH; Reis-Filho JS; Zamarin D; Weigelt B
Gynecol Oncol; 2021 May; 161(2):545-552. PubMed ID: 33674143
[TBL] [Abstract][Full Text] [Related]
17. Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer.
Da Cruz Paula A; DeLair DF; Ferrando L; Fix DJ; Soslow RA; Park KJ; Chiang S; Reis-Filho JS; Zehir A; Donoghue MTA; Wu M; Brown DN; Murali R; Friedman CF; Zamarin D; Makker V; Mueller JJ; Leitao MM; Abu-Rustum NR; Aghajanian C; Weigelt B
Gynecol Oncol; 2021 May; 161(2):535-544. PubMed ID: 33622519
[TBL] [Abstract][Full Text] [Related]
18. Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis.
Mukherjee R; Vanaja KG; Boyer JA; Gadal S; Solomon H; Chandarlapaty S; Levchenko A; Rosen N
Mol Cell; 2021 Feb; 81(4):708-723.e5. PubMed ID: 33606974
[TBL] [Abstract][Full Text] [Related]
19. CRISPR-Based Gene Editing: a Modern Approach for Study and Treatment of Cancer.
Talukder P; Chanda S; Chaudhuri B; Choudhury SR; Saha D; Dash S; Banerjee A; Chatterjee B
Appl Biochem Biotechnol; 2023 Sep; ():. PubMed ID: 37737443
[TBL] [Abstract][Full Text] [Related]
20. IGFBP1 Sustains Cell Survival during Spatially-Confined Migration and Promotes Tumor Metastasis.
Cai G; Qi Y; Wei P; Gao H; Xu C; Zhao Y; Qu X; Yao F; Yang W
Adv Sci (Weinh); 2023 Jul; 10(21):e2206540. PubMed ID: 37296072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
